Holen Sie sich die Stockscreener-App
155.51
0.78%
-1.23
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$156.74
Offen:
$156.7
24-Stunden-Volumen:
1.42M
Relative Volume:
0.87
Marktkapitalisierung:
$22.80B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
14.88
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+0.80%
1M Leistung:
+2.17%
6M Leistung:
+32.68%
1J Leistung:
-10.59%
1-Tages-Spanne:
$151.83
$156.70
1-Wochen-Bereich:
$148.51
$157.80
52-Wochen-Spanne:
$110.03
$175.86
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
155.51 | 22.99B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
924.37 | 839.03B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.57 | 450.47B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
219.16 | 387.13B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.35 | 242.86B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
86.28 | 212.91B | 63.90B | 19.05B | 14.72B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc.’s volatility index tracking explained2025 Biggest Moves & Stock Portfolio Risk Control - newser.com
Stifel Upgrades Biogen (BIIB) - Nasdaq
Biogen Shares Rise After Stifel Upgrade - MarketScreener
Biogen (BIIB) Valuation in Focus After Q3 Earnings Growth and Share Buyback Update - simplywall.st
Why Biogen Inc. (IDP) stock stays on top picksWeekly Volume Report & AI Driven Price Predictions - newser.com
December 26th Options Now Available For Biogen (BIIB) - Nasdaq
Historical volatility pattern of Biogen Inc. visualized2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - MSN
Stifel Upgrades Biogen (BIIB) to 'Buy', Raises Price Target to $202 | BIIB Stock News - GuruFocus
Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift - Yahoo! Finance UK
Here Are Thursday's Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - 24/7 Wall St.
Will Biogen Inc. stock benefit from upcoming earnings reportsRisk Management & Technical Pattern Based Signals - fcp.pa.gov.br
Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift By Investing.com - Investing.com Canada
Using portfolio simulators with Biogen Inc. included2025 Institutional Moves & Short-Term Trading Alerts - newser.com
Stifel Upgrades Biogen to Buy From Hold, Adjusts Price Target to $202 From $144 - MarketScreener
Exclusive: Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs - Reuters
Progressive Supranuclear Palsy Treatment Market Generated - openPR.com
Backtesting results for Biogen Inc. trading strategiesNew Guidance & Daily Price Action Insights - newser.com
Key metrics from Biogen Inc.’s quarterly data2025 Volume Leaders & Weekly Stock Performance Updates - newser.com
5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call - The Globe and Mail
Why Biogen Inc. stock is seen as undervaluedWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - fcp.pa.gov.br
When is the best time to exit Biogen Inc.Market Performance Recap & Low Risk Growth Stock Ideas - newser.com
Analyzing Biogen Inc. with multi timeframe chartsMarket Trend Report & Growth Focused Entry Reports - newser.com
Institutional scanner results for Biogen Inc.July 2025 Final Week & Weekly Top Performers Watchlists - newser.com
How to escape a deep drawdown in Biogen Inc.July 2025 Action & Community Consensus Stock Picks - newser.com
Will Biogen Inc. (IDP) stock benefit from commodity supercycleDay Trade & Weekly Market Pulse Updates - newser.com
Is Biogen Inc. stock a top momentum playJuly 2025 News Drivers & Real-Time Buy Signal Alerts - newser.com
How Biogen Inc. (IDP) stock behaves in tightening cyclesLong Setup & Detailed Earnings Play Alerts - newser.com
Biogen Fights To Defend MS Franchise Amid Generic Erosion And Biosimilar Threats - Citeline News & Insights
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
$185 million, proven team lead startup Braveheart Bio's toward late-stage heart drug trial - The Business Journals
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Should you wait for a breakout in Biogen Inc.Trade Analysis Summary & Low Risk Entry Point Tips - newser.com
Retirement Systems of Alabama Cuts Holdings in Biogen Inc. $BIIB - MarketBeat
Will Biogen Inc. (IDP) stock benefit from sector leadership2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Central Nervous System Disorders Therapeutics Market to Expand - openPR.com
Volatility clustering patterns for Biogen Inc.Weekly Market Summary & Stock Market Timing Techniques - newser.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Stoke Therapeutics Q3 revenue beats estimates on Acadia, Biogen agreements - MarketScreener
[Form 4] BIOGEN INC. Insider Trading Activity - Stock Titan
Biogen to Participate in Upcoming Investor Conferences - Biogen
Biogen’s yearslong lupus R&D journey could soon pay off - PharmaVoice
Sanford C. Bernstein Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Chart based exit strategy for Biogen Inc.Trade Volume Summary & Growth Focused Investment Plans - newser.com
Recombinant DNA Technology Market Surges with Breakthrough - openPR.com
Biogen Inc. $BIIB Shares Sold by iA Global Asset Management Inc. - MarketBeat
Biogen to present felzartamab data at Kidney Week 2025 By Investing.com - Investing.com Nigeria
Bernstein Maintains Biogen (BIIB) Market Perform Recommendation - Nasdaq
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Behavioral Patterns of BIIB and Institutional Flows - news.stocktradersdaily.com
BIIB: Bernstein Raises Price Target for Biogen to $157 with Mark - GuruFocus
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):